SENIORS Trial: Nebivolol in Elderly HFrEF
European Heart Journal (2005)
Reduced composite of death/CV hospitalization by 14% in 2,128 elderly HFrEF patients.
Nebivolol
Oral tablet (5mg)Available in all 50 statesMarketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
heart
NebivololNebivolol
Third-generation beta-1 selective blocker with unique NO-enhancing mechanism via beta-3 receptor agonism and eNOS stimulation. Metabolically neutral, does not worsen insulin resistance or dyslipidemia unlike older beta-blockers.
Metabolically neutral, no insulin resistance or dyslipidemia worsening
NO-mediated vasodilation improves endothelial function
Less fatigue and ED than older beta-blockers
14% mortality reduction in elderly HFrEF (SENIORS)
No commitment · HSA/FSA eligibleNo commitment · HSA/FSA eligible
How it works
Mechanism of action
Highly selective beta-1 blockade reduces HR and cardiac output. Additionally stimulates beta-3 receptors on endothelial cells, activating eNOS and producing vasodilation via NO pathway. Dual mechanism distinguishes from older beta-blockers.
The baseline panel.
Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →
Hormone Profile
12 markers
Sex hormones
- Total TestosteroneLC/MS
- Free TestosteroneEquilibrium Dialysis
- Estradiol, Sensitive / UltrasensitiveLC/MS
- Sex Hormone Binding Globulin (SHBG)
- ProgesteroneLC/MSFemale panel
- Prolactin
- Luteinizing Hormone (LH)
- Follicle-Stimulating Hormone (FSH)
- hCG, Total, QuantitativeFemale panel, pre-menopause
Adrenals & neurosteroids
- Cortisol
- DHEA-S
Growth hormone / IGF-1
- Insulin-Like Growth Factor I (IGF-1)
Thyroid Status
3 markers
Thyroid hormones
- Thyroid Stimulating Hormone (TSH)
- Free T4
- Free T3
Heart Health
9 markers
Cardiovascular health
- Total Cholesterol
- HDL Cholesterol
- LDL Cholesterol
- LDL:HDL Ratio
- VLDL Cholesterol
- Triglycerides
- Apolipoprotein-B (ApoB)
- C-Reactive Protein, High Sensitivity (hsCRP)
- Lipoprotein(a) (Lp(a))
Metabolism
3 markers
Insulin sensitivity
- Blood Glucose
- Fasting Insulin
- HbA1c
Organ Function
26 markers
Liver & pancreas
- AST
- ALT
- Bilirubin, Total
- γ-Glutamyl Transferase (GGT)
Kidney function
- BUN
- Creatinine w/ eGFR
Comprehensive Metabolic Panel (CMP)
- Glucose
- Blood Urea Nitrogen (BUN)
- Creatinine
- eGFR
- BUN/Creatinine Ratio
- Sodium
- Potassium
- Chloride
- Carbon Dioxide, Total
- Calcium
- Protein, Total
- Albumin
- Globulin, Total
- Albumin/Globulin (A/G) Ratio
- Alkaline Phosphatase (ALP)
- AST
- ALT
Prostate health
- Prostate-Specific Antigen (PSA)Male panel
- Free PSAMale panel
- % Free PSAMale panel
Nutrient Status
31 markers
Vitamins & minerals
- Vitamin D, 25-OHD (25-Hydroxy)
- Magnesium, RBC
Iron status
- Iron
- Iron Saturation
- TIBC
- UIBC
- Ferritin
Complete Blood Count (CBC)
- White Blood Count (WBC)
- Red Blood Count (RBC)
- Hemoglobin (Hgb)
- Hematocrit (HCT)
- MCV
- MCH
- MCHC
- Red Cell Distribution Width (RDW)
- Platelets
- Neutrophils
- Neutrophils (Absolute)
- Lymphocytes
- Lymphocytes (Absolute)
- Neutrophil/Lymphocyte Ratio
- Monocytes
- Monocytes (Absolute)
- Eosinophils
- Eosinophils (Absolute)
- Basophils
- Basophils (Absolute)
- Immature Cells
- Immature Granulocytes
- Immature Granulocytes (Absolute)
- NRBC, w/ Reflex for Immature Cells
Clinical evidence
The research behind Nebivolol.
Safety profile
Monitoring & safety information.
Commonly reported side effects
- Bradycardia
- Fatigue (less than older beta-blockers)
- Headache
- Dizziness
Less common but serious risks
- Severe bradycardia/heart block
- Bronchospasm (possible)
- Masking hypoglycemia
- Withdrawal syndrome
Generally not appropriate for
- Severe bradycardia (<50 bpm)
- Sick sinus syndrome
- 2nd/3rd degree heart block
- Decompensated HF
- Severe asthma
Typical monitoring
- Heart rate and BP
- ECG at baseline
- Fasting glucose and lipids
- Pulmonary symptoms
FAQ
Quick answers.
Third-generation beta-1 selective blocker with unique NO-enhancing mechanism via beta-3 receptor agonism and eNOS stimulation. Metabolically neutral, does not worsen insulin resistance or dyslipidemia unlike older beta-blockers.
Metabolically neutral, no insulin resistance or dyslipidemia worsening. NO-mediated vasodilation improves endothelial function. Less fatigue and ED than older beta-blockers. 14% mortality reduction in elderly HFrEF (SENIORS).
Common side effects include: bradycardia, fatigue (less than older beta-blockers), headache, dizziness. Most side effects are dose-dependent and may resolve with continued use or dose adjustment.
Third-generation beta-1 selective blocker with unique NO-enhancing mechanism via beta-3 receptor agonism and eNOS stimulation. Metabolically neutral, does not worsen insulin resistance or dyslipidemia unlike older beta-blockers.
Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.